FEB 10, 2021 2:10 PM PST

Genetics Affect Response to Cancer Immunotherapy

WRITTEN BY: Annie Lennon

Researchers have found that genetic factors may dictate as much as 20% of the efficacy of checkpoint inhibitors, a kind of immunotherapy that releases the immune system's brakes so it can better attack cancer cells. 

For the study, they used data from The Cancer Genome Atlas and ultimately analyzed the genes and immune responses of 9,000 patients with 30 different kinds of cancer. All in all, they examined 11 million gene variants and how they correlated with 139 immune parameters measured in the patients' tumor samples. 

Previous studies found that those who respond best to immunotherapies tend to have 'inflamed tumors'- tumors that have been infiltrated by immune cells capable of fighting off viruses and cancer cells. As such, the researchers looked for markers of inflamed tumors among cancer patients in their data set. 

In doing so, they identified 22 regions of the genome or individual genes that played a large role in the immune response. In particular, they identified one gene, known as IFIH1, which is already known to influence autoimmune diseases like type 1 diabetes, psoriasis, and Crohn's disease. 

Regarding cancer immunity, patients with the Type 1 diabetes variant of IFIH1 had more inflamed tumors, suggesting they would respond better to cancer immunotherapy. Those with gene variant linked to Crohn's disease, however, had less inflamed tumors, suggesting they would respond worse to the treatment.  

The researchers also identified STING1, a gene already known to play a role in patients' response to immunotherapy. While drug companies are researching ways to amplify its effects, the present study found that a variant of the gene makes people less likely to respond to immunotherapy. 

"Rather than testing selected genes, we analyzed all the genetic variants we could detect across the entire genome. Among all of them, the ones with the greatest effect on the immune system's response to the tumor were related to interferon signaling. Some of these variants are known to affect our response to viruses and our risk of autoimmune disorders," says Davide Bedognetti, co-senior author of the paper. 

"As observed with other diseases, we demonstrated that specific genes can also predispose someone to have a more effective anti-cancer immunity."

 

Sources: EurekAlertCell

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
DEC 29, 2020
Cannabis Sciences
What Happens When You Combine Cannabis with Psychedelics?
DEC 29, 2020
What Happens When You Combine Cannabis with Psychedelics?
Despite the growing popularity of cannabis and psychedelics, there is a shortage of research on how the two interact. Be ...
JAN 11, 2021
Cell & Molecular Biology
Ginger May Help Slow Lupus or Antiphospholipid Syndrome Progression
JAN 11, 2021
Ginger May Help Slow Lupus or Antiphospholipid Syndrome Progression
Naturally occurring chemicals make more appealing medicines for many people, but there is not always evidence that they' ...
MAR 01, 2021
Microbiology
New Therapeutic Potential for a 'Miracle Poison'
MAR 01, 2021
New Therapeutic Potential for a 'Miracle Poison'
Most people know botulism as a nasty disease and botox as a wrinkle reducer that may cause a 'frozen' look if it's overu ...
MAR 09, 2021
Cannabis Sciences
Top Benefits of Having Your Medical Marijuana Card
MAR 09, 2021
Top Benefits of Having Your Medical Marijuana Card
With the use of medicinal marijuana booming, estimated at almost 4.5 million patients in 2020, it’s time to talk a ...
APR 01, 2021
Immunology
Tumor-Killing 101: Vaccine Trains Immune Cells to Keep Skin Cancer at Bay
APR 01, 2021
Tumor-Killing 101: Vaccine Trains Immune Cells to Keep Skin Cancer at Bay
Cancer researchers have developed a therapeutic vaccine for melanoma, a deadly form of skin cancer. Instead of protectin ...
APR 10, 2021
Drug Discovery & Development
How New ADHD Drug for Children Differs from Adderall
APR 10, 2021
How New ADHD Drug for Children Differs from Adderall
Over 1 in 10 children in the US aged between 5 and 17 have been diagnosed with attention deficit hyperactivity ...
Loading Comments...